Nassau County, NY v. Mylan Pharmaceuticals, Inc.

CourtDistrict Court, E.D. New York
DecidedFebruary 28, 2025
Docket2:23-cv-05382
StatusUnknown

This text of Nassau County, NY v. Mylan Pharmaceuticals, Inc. (Nassau County, NY v. Mylan Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nassau County, NY v. Mylan Pharmaceuticals, Inc., (E.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------------------X NASSAU COUNTY, NY,

Plaintiff, REPORT AND RECOMMENDATION -against- 23-CV-5382 (OEM) (ARL)

MYLAN PHARMACEUTICALS, INC., et al.,

Defendants. ---------------------------------------------------------------------X LINDSAY, Magistrate Judge:

Before the Court, on referral from District Judge Merchant, is the plaintiff's motion for an award of attorneys’ fees. For the reasons set forth below, the undersigned respectfully recommends that the plaintiff’s motion be denied. BACKGROUND The plaintiff, Nassau County (the “County”), commenced this action in the Suffolk County Supreme Court, seeking money damages for the financial losses it suffered combating the opioid epidemic. In July 2017, the New York State Court Litigation Coordination Panel issued an order requiring that any opioid matters filed in the state court similar to the instant action be transferred for coordination to the Suffolk County Supreme Court under the caption In re Opioid Litigation, Index No. 400000/2017. ECF No. 109. In late 2021, some of the cases, including this case, were selected for a bellwether trial that reached a verdict against several defendants on the issue of liability. Id. In April 2023, following the trial, the County amended its complaint to add pharmacy benefit managers as defendants including OptumRx, Inc. (“OptumRx”) and Express Scripts, Inc., (“Express Scripts”). On July 15, 2023, the case was removed to this Court by OptumRx pursuant to 28 U.S.C. § 1442(a), the federal-officer removal statute. ECF No. 1. On July 28, 2023, Express Scripts filed its own supplemental notice of removal under the same statute. ECF No. 21. Although OptumRx and Express Scripts are both private parties, not federal officers, they argued that they had a colorable government contract defense because they were parties to contracts with various federal agencies and were acting at the direction and supervision of the federal government.

On August 3, 2023, the County filed a premotion conference letter with the Court indicating that it planned to file a motion to remand the case back to the state court in Westchester County where claims in Non-Track I matters were being addressed. However, two weeks later, before it filed the motion, the County contacted the removing defendants and offered to stipulate to disclaim all federal claims and any basis for removal under the federal officer removal statute. OptumRx and Express Scripts rejected the offer to stipulate. Then, on October 11, 2023, in an effort to further resolve the issues surrounding the anticipated motion to remand, the County filed a motion seeking to amend its complaint, this time to carve out allegations used to support the notices of removal based exclusively on the federal officer statute. The motion to amend was granted on October 16, 2023. The amended complaint, which became the operative

pleading, included a disclaimer of any claims for conduct by the defendants under contracts with the federal government or officers and those regarding federal plan beneficiaries, military personnel, veterans or others under the specific federal plans identified in the notices of removal. On December 7, 2023, the County filed the motion to remand. The County argued, as it had in the premotion conference letter, that it was not asserting claims that were federal in character related to opioids prescriptions adjudicated or processed under federal programs, contracts, or plans or claims involving federal officers, contracts, claims and/or beneficiaries. Specifically, the County indicated that its allegations were never intended to implicate federal customers, programs, or agencies like the Veterans Health Administration (“VHA”), the Department of Defense’s (“DoD”) TRICARE operations or the Office of Personnel Management’s (“OPM”) Federal Employee Health Benefits (“FEHB”) program, nor did its claims challenge the administration of any such programs by a third party. By order dated July 4, 2024, the Court granted the County’s motion and remanded the

case back to the Suffolk County Supreme Court, Index No. 400008/2017, for all further proceedings. In its decision, the Court highlighted the fact that the federal claims had been abandoned. The Court further noted that the new allegations were sufficiently tailored to renounce any claims for recovery related to OptumRx and Express Script’s services, conduct, and contracts in connection with TRICARE, the FEHB, the VHA or any other federal program. Two weeks after the case was closed, the County filed the instant motion for attorneys’ fees arguing that the defendants had lacked an objectively reasonable basis to maintain the case in federal court. DISCUSSION A. Standards of Law

Under 28 U.S.C. § 1447(c), “[a]n order remanding [a] case may require payment of just costs and any actual expenses, including attorney fees, incurred as a result of the removal.” Westchester Cnty. v. Mylan Pharms., Inc., No. 23-CV-6096 (CS), 2025 WL 369716, at *2 (S.D.N.Y. Feb. 3, 2025) (citing 28 U.S.C. § 1447(c)(emphasis added)). The standard for awarding fees under the statute turns on the reasonableness of the removal. Martin v. Franklin Cap. Corp., 546 U.S. 132, 141, 126 S. Ct. 704, 711, 163 L. Ed. 2d 547 (2005). “Absent unusual circumstances, courts may award attorney's fees under § 1447(c) only where the removing party lacked an objectively reasonable basis for seeking removal. Conversely, when an objectively reasonable basis exists, fees should be denied.” Id. “A basis for removal is objectively reasonable if the removing party had a colorable argument that removal was proper.” Westchester Cnty., 2025 WL 369716, at *2 (citing Capital2Market Consulting, LLC v. Camston Wrather, LLC, No. 22-CV-7787, 2023 WL 2366975, at *4 (S.D.N.Y. Mar. 6, 2023)). In other words, “[i]f a defendant's grounds for removal are not clearly barred by established federal law,

then an award of attorney's fees and costs is improper.” Id. (citing Little Rest Twelve, Inc. v. Visan, 829 F. Supp. 2d 242, 245 (S.D.N.Y. 2011)). B. The Objectively Reasonable Basis for Removal In this case, the County argues that it is entitled to an award of attorneys’ fees because OptumRx and Express Script lacked an objectively reasonable basis for removing the case after it offered to stipulate to disclaim all federal claims and even filed an amended complaint to further effectuate the disavowal of any claims that might have formed a basis for removal under the federal officer removal statute. However, the Second Circuit has made clear that under § 1447(c), “[o]bjective reasonableness is evaluated based on the circumstances as of the time that the case was removed.” Williams v. Int'l Gun-A-Rama, 416 F. App'x 97, 99 (2d Cir. 2011). This

case was removed to the Court in mid-July 2023. The County did not contact the defendants to propose entering into the stipulation until mid-August. It did not file the amended complaint expressly disavowing the claims until October. Indeed, in July, when Optum Rx removed the case to this Court, the operative pleading was the amended complaint filed in April 2023.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Martin v. Franklin Capital Corp.
546 U.S. 132 (Supreme Court, 2005)
Williams v. International Gun-A-Rama
416 F. App'x 97 (Second Circuit, 2011)
Calabro v. Aniqa Halal Live Poultry Corp.
650 F.3d 163 (Second Circuit, 2011)
Savoie v. Merchants Bank
84 F.3d 52 (Second Circuit, 1996)
Savino v. Kerwick Savino
590 F. App'x 80 (Second Circuit, 2015)
CMGRP, Inc. v. Agency for the Performing Arts, Inc.
689 F. App'x 40 (Second Circuit, 2017)
Little Rest Twelve, Inc. v. Visan
829 F. Supp. 2d 242 (S.D. New York, 2011)
Connecticut Ex Rel. Tong v. Exxon Mobil Corp.
83 F.4th 122 (Second Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Nassau County, NY v. Mylan Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/nassau-county-ny-v-mylan-pharmaceuticals-inc-nyed-2025.